B. Riley Wealth Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

B. Riley Wealth Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3,094	Closed	-$24	–	2692
2014 Q4	$24	Buy	+3,094	New	+$24.5K	﹤0.01%	2472
2014 Q3	–	Sell	-36	Closed	-$348	–	2504
2014 Q2	$348	Buy	+36	New	+$321	﹤0.01%	2361

Other funds holding PDLI

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

B. Riley Wealth Advisors's PDLI Position: Q1 2015 in Review

B. Riley Wealth Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2015, closing a stake of 3,094 shares — an estimated $24 sold.

B. Riley Wealth Advisors first reported a position in PDLI in Q2 2014 and held it in 2 quarters. The position peaked at $348 in Q2 2014. 215 funds tracked by Wall St. Rank hold PDLI as of Q1 2015.

B. Riley Wealth Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2015 after selling out during the quarter.
B. Riley Wealth Advisors sold 3,094 PDL BioPharma, Inc. shares in Q1 2015, an estimated $24.
B. Riley Wealth Advisors first reported a position in PDL BioPharma, Inc. in Q2 2014 and held it in 2 quarters.
B. Riley Wealth Advisors's PDL BioPharma, Inc. position peaked at $348 in Q2 2014.
215 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2015.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2015, filed 14 May 2015.